...
首页> 外文期刊>Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies >A Pilot Study of the Association of Amino-Terminal Pro-B-Type Natriuretic Peptide and Severity of Illness in Pediatric Septic Shock
【24h】

A Pilot Study of the Association of Amino-Terminal Pro-B-Type Natriuretic Peptide and Severity of Illness in Pediatric Septic Shock

机译:氨基 - 末端Pro-B型利钠肽和疾病严重程度的试验研究

获取原文
获取原文并翻译 | 示例

摘要

Objectives: Biomarkers that can measure illness severity and predict the risk of delayed recovery may be useful in guiding pediatric septic shock. Amino-terminal pro-B-type natriuretic peptide has not been assessed in pediatric septic patients at the time of presentation to the emergency department prior to any interventions. The primary aim was to assess if emergency department amino-terminal pro-B-type natriuretic peptide is associated with worse outcomes and severity of illness. Design: Prospective observational pilot study. Settings: Tertiary free-standing children's hospital. Patients: Children 0-17 years old with a diagnosis of septic shock were enrolled. Patients with preexisting cardiac and renal dysfunction were excluded. Interventions: None. Measurements and Main Results: Amino-terminal pro-B-type natriuretic peptide analysis was performed on samples obtained in the emergency department prior to any intervention. The association between biomarkers and clinical outcomes and illness severity using Pediatric RISk of Mortality 3 were assessed. Eighty-two patients with septic shock underwent analysis. The median (interquartile range) amino-terminal pro-B-type natriuretic peptide levels was 394 pg/mL (102-1,392 pg/mL). Each decile change increase in amino-terminal pro-B-type natriuretic peptide was associated with a change in ICU length of stay by 8.7%, (95% CI, 2.4-15.5), hospital length of stay by 5.7% (95% CI, 0.4-11.2), organ dysfunction by 5.1% (95% CI, 1.8-8.5), a higher inotropic score at 12, 24, and 36 hours, and longer time requiring vasoactive agents. There was a significant correlation between baseline amino-terminal pro-B-type natriuretic peptide and the Pediatric RISk of Mortality 3 score (Spearman rho = 0.247; p = 0.029). Conclusions: This pilot study shows an association between emergency department amino-terminal pro-B-type natriuretic peptide on presentation and worse septic shock outcomes and amino-terminal pro-B-type natriuretic peptide levels correlates with an ICU severity score.
机译:目的:可以测量疾病严重程度和预测延迟恢复的风险的生物标志物可用于引导小儿脓毒症休克。在任何干预措施之前,在给予急诊部门的小儿脓毒症患者中尚未评估氨基 - 末端Pro-B型利钠肽。主要目的是评估急诊系氨基末端Pro-B型Natrietic肽是否与较差的结果和疾病严重程度有关。设计:预期观测试验研究。设置:高等级自由驻生儿童医院。患者:0-17岁儿童诊断脓毒症休克诊断。患有先前存在的心脏和肾功能障碍的患者。干预措施:没有。测量和主要结果:在任何干预之前对急诊部中获得的样品进行氨基 - 末端Pro-B型利钠肽分析。评估生物标志物和临床结果与疾病严重程度的协会,使用儿科的死亡风险3进行了评估。八十二患者渗透休克接受分析。中位数(四分位数)氨基 - 末端Pro-B型利钠肽水平为394pg / ml(102-1,392pg / ml)。氨基 - 末端Pro-B型利钠肽的每条标准变化增加与ICU的变化与ICU的变化保持8.7%,(95%CI,2.4-15.5),医院入住时间为5.7%(95%CI ,0.4-11.2),器官功能障碍5.1%(95%CI,1.8-8.5),在12,24和36小时的较高的肌室得分,较长的时间需要血管活性剂。基线氨基 - 末端Pro-B型利钠肽与死亡率3分的儿科风险之间存在显着相关性(Spearman Rho = 0.247; P = 0.029)。结论:该试点研究表明,急诊部氨基末端Pro-B型利钠肽之间的关联,呈现和更差的脓毒性冲击结果和氨基 - 末端Pro-B型Natrietic肽水平与ICU严重程度分数相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号